期刊
BIOMEDICAL CHROMATOGRAPHY
卷 23, 期 7, 页码 707-713出版社
WILEY
DOI: 10.1002/bmc.1173
关键词
topotecan; HPLC; whole blood; pharmacokinetics
类别
资金
- NCI NIH HHS [P01 CA023099-319005, CA 21765, CA 23099, P30 CA021765, P01 CA023099] Funding Source: Medline
Individualization of topotecan dosing reduces inter-patient variability in topotecan exposure, presumably reducing toxicity and increasing efficacy. However, logistical limitations (e.g. requirement for plasma, intensive bedside plasma processing) have prevented widespread application of this approach to dosing topotecan. Thus, the objectives of the present study were to develop and validate an HPLC with fluorescence detection method to measure topotecan lactone in whole blood samples and to evaluate its application to individualizing topotecan dosing. Plasma samples (200 mu L) were prepared using methanolic precipitation, a filtration step and then injection of 100 mu L of the methanolic extract onto a Novapak (R) C-18, 4 mu m, 3.9 x 150 mm column with an isocratic mobile phase. Analytes were detected with a Shimadzu Fluorescence RF-10AXL detector with an excitation and emission wavelength of 370 and 520 nm, respectively. This method had a lower limit of quantification of 1 ng/mL (S/N >= 5; RSD 4.9%) and was validated over a linear range of 1-100 ng/mL. Results from a 5-day validation study demonstrated good within-day and between-day precision and accuracy. Data are presented to demonstrate that the present method can be used with whole blood samples to individualize topotecan dosing in children with cancer. Copyright (C) 2009 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据